- In November 2023, The FDA approved Eli Lilly’s Zepbound (tirzepatide) injection as the first obesity treatment targeting both GIP and GLP-1 hormone receptors. This groundbreaking drug is indicated for adults with obesity or overweight, particularly those with related medical conditions. When combined with a reduced-calorie diet and increased physical activity, Zepbound aids in significant weight loss, offering a novel solution for managing obesity
- In October 2023, Eli Lilly and Company presented results from two Phase 3 trials, LIBRETTO-431 and LIBRETTO-531, at the ESMO Congress 2023. These trials evaluated Retevmo (selpercatinib) in RET fusion-positive non-small cell lung cancer (NSCLC) and RET-mutant medullary thyroid cancer (MTC). In both cases, Retevmo demonstrated promising efficacy, outperforming chemotherapy and multi-kinase inhibitors, making it a promising treatment for these advanced cancers
- In April 2023, Eli Health raised USD 3.6 million to develop saliva-based continuous hormone monitoring technology. Initially focusing on menopause, fertility, and general health, the technology aims to empower women with real-time insights into their hormonal health. Future expansion plans include addressing contraception and endocrine diseases once regulatory approvals and clinical validations are completed, potentially transforming women's health monitoring
- In August 2022, The FDA approved the Mira Ovum Wand, an over-the-counter device that detects follicle-stimulating hormone (FSH) levels in urine. This tool enables women to monitor their fertility at home with ease and accuracy. The Mira Ovum Wand offers a new, accessible option for women tracking ovulation, helping with family planning and improving overall reproductive health management
- In May 2022, Inne.io, based in Berlin, secured an additional EUR 9.3 million to expand its hormone-tracking technology. This funding aims to help women better understand and manage their reproductive health. The company focuses on providing accessible hormone tracking solutions, with plans to eventually broaden its offerings to include other areas such as fertility and contraception, potentially revolutionizing the way women track their hormonal health
- In March 2021, Abbott Laboratories launched the Alinity m Diagnostics System, a high-throughput, automated platform for immunoassay testing. The system enables rapid and accurate diagnostic testing for endocrine-related conditions and other medical tests. With its quick turnaround time and advanced technology, the Alinity m system significantly improves diagnostic efficiency, enhancing Abbott’s position in the medical diagnostics market and contributing to improved patient care
- In February 2021, Siemens Healthineers introduced the Atellica Solution for Endocrinology, a comprehensive, fully automated immunoassay system. Designed for endocrinology testing, this system provides precise and reliable results for a broad spectrum of hormone markers. The launch of the Atellica Solution bolstered Siemens’ product portfolio, enhancing its ability to meet the growing demand for accurate, automated testing solutions in the healthcare sector
Frequently Asked Questions
The market is segmented based on Segmentation, By Test (Thyroid Test, Insulin Test, Dehydroepiandrosterone sulfate (DHEAS), Human Chorionic Gonadotropin Test, Human Chorionic Gonadotropin (HCG), Follicle Stimulating (FSH), Prolactin Test, Luteinizing Hormone Test, Progesterone Test, and Others), Technology (Immunoassay, Monoclonal and Polyclonal Antibody Technologies, Clinical Chemistry Technologies, Tandem Mass Spectroscopy, Sensor Technology, and Others), End-User (Hospitals, Clinical Laboratories, and Others) – Industry Trends and Forecast to 2032
.
The Global Endocrine Testing Market size was valued at USD 11.39 USD Billion in 2024.
The Global Endocrine Testing Market is projected to grow at a CAGR of 5.88% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
